JACN Did you know that you can get alerts when a new issue is online?
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Figures Only
Right arrow Full Text (PDF)
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Anderson, J. W.
Right arrow Articles by Jenkins, D. J.A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Anderson, J. W.
Right arrow Articles by Jenkins, D. J.A.
Journal of the American College of Nutrition, Vol. 22, No. 5, 331-339 (2003)
Published by the American College of Nutrition

Review

Importance of Weight Management in Type 2 Diabetes: Review with Meta-analysis of Clinical Studies

James W. Anderson, MD, FACN, Cyril W.C. Kendall, PhD, FACN and David J.A. Jenkins, MD, PhD, DSc, FACN

Department of Internal Medicine, College of Medicine, University of Kentucky, Lexington, KY (J.W.A.)
Risk Factor Medical Center, St. Michael’s Hospital and Department of Nutrition, University of Toronto, Toronto, CANADA (C.W.C.K., D.J.A.J.)

Address correspondence to: James W. Anderson, MD, Metabolic Research Group, 1030 S. Broadway St., Suite 5, Lexington, KY 40504-2681. E-mail: jwandersmd{at}aol.com


   ABSTRACT
TOP
 FOOTNOTES
 ABSTRACT
INTRODUCTION
 REFERENCES
 
Obesity is a major risk factor for development of diabetes, and excessive energy intake is a major contributor to poor glycemic control in Type 2 diabetes. The impact of obesity on risk for diabetes as well as coronary heart disease (CHD) risk factors and the benefits of weight loss in decreasing risk for developing diabetes and improving glycemia and CHD risks were reviewed. A systematic review of the medical literature to assess the impact of obesity and weight gain on risk for diabetes and CHD was done. We performed a meta-analysis of the effects of weight loss for obese diabetic individuals. Controlled clinical trials assessing lifestyle changes on risk for developing diabetes and weight loss effects on glycemia and CHD risk factors were reviewed. Obesity and weight gain can increase risk for diabetes by greater than ninetyfold and CHD by about sixfold. Very-low-energy diets (VLED) decrease fasting plasma glucose values by ~50% within two weeks and these changes are sustained with continued energy restriction. Twelve weeks of energy-restricted diets were associated with these significant decreases: body weight, 9.6%; fasting plasma glucose, 25.7%; serum cholesterol, 9.2%; serum triglycerides, 26.7%; systolic blood pressure, 8.1%; and diastolic blood pressure, 8.6%. Larger weight losses were associated with larger reductions in these values. The reviewed data suggest that US health care providers should endorse the American Heart Association’s and European diabetes associations’ recommendations that diabetic persons achieve and maintain a BMI of <=25 kg/m2. Weight management may be the most important therapeutic task for most obese Type 2 diabetic individuals.

Key words: diabetes, obesity, coronary heart disease, weight loss, diabetes risk

Key teaching points:

• From 60% to 90% of Type 2 diabetes mellitus appears related to obesity or weight gain.

• Obesity of weight gain can increase the risk for developing diabetes by greater than ninetyfold.

• Obesity or weight gain can increase the risk for coronary heart disease in women by sixfold.

• Weight loss of 10% of initial body weight dramatically improves glycemic control and reduces lipid and blood pressure co-morbid risks.

• A weight goal of a body mass index <=25 kg/m2 is recommended for persons with Type 2 diabetes mellitus.

• Weight management appears to be the most important therapeutic task for most Type 2 diabetic individuals.


   INTRODUCTION
TOP
 FOOTNOTES
 ABSTRACT
 INTRODUCTION
REFERENCES
 
Diabetes and obesity are emerging at epidemic rates in the US [1,2] as is Type 2 diabetes in adolescents [3]. Because obesity or weight gain have such an important role in the pathophysiology of diabetes [4,5], there is an urgent need to implement nutrition strategies to prevent, ameliorate and manage these problems. Further stimulation to action comes from evidence indicating that weight loss reduces premature mortality for diabetic individuals [6,7].

Obesity and diabetes have become so inseparable that they are like "conjoined twins." Women who were obese at 18 years of age and gain further weight have a risk for developing by diabetes that reaches greater than ninetytwofold the risk for women who were slender at age 18 and did not gain weight [4]. An estimated 60% to 90% of Type 2 diabetes is related to obesity [8–10]. Obesity may be the most impacting risk factor for CHD in non-diabetic individuals [11] and is probably even more important for individuals with diabetes [12,13]. Since CHD is responsible for about 70% to 80% of the deaths in persons with diabetes, addressing this obesity-diabetes connection is vital for adults with diabetes [13,14]. Unfortunately, most pharmacologic approaches for diabetes contribute to weight gain [15], as does intensive therapy [16,17]. This review was stimulated by the possibility that weight management should receive a higher priority in the management of certain obese individuals with diabetes.

To reassess treatment goals and strategies for obese diabetic individuals the following areas were assessed: effect of obesity or weight gain on risk for developing diabetes; impact of obesity or weight gain on risk for coronary heart disease (CHD), the major cause of death in diabetes; influence of diet on risk factors for CHD, diabetes and glycemic control; burden of CHD associated with diabetes; weight loss outcomes for persons with Type 2 diabetes; weight management recommendations.

Obesity and Weight Change Effects on Diabetes Risk
Obesity is the major risk factor for development of diabetes, accounting for 60% to 90% of the variance [8,9]. Colditz and colleagues [4] from the Nurses’ Health Study assessed the impact of three different factors on risk for developing diabetes in women: (1) BMI at age 18 years, an assessment of adolescent obesity, (2) weight gain after age 18, and (3) attained BMI at 30 to 55 years of age, assessing adolescent obesity as well as weight gain. The diagnosis of diabetes was based on either elevated plasma glucose levels or treatment with oral hypoglycemic agents or insulin. The age-adjusted risk for developing diabetes over 14 years of age increased from a standardized risk of 1.0 for a BMI of <22 kg/m2 at age 18 to a relative risk (RR) of 93.2 for an attained BMI of >=35.0 at 30 to 55 years of age. Knowler and colleagues [10] reported remarkably similar risks for diabetes associated with obesity in Pima Indians who had one or both parents with diabetes. The incidence of diabetes was determined by glucose tolerance test. They noted that the age-adjusted RR for developing diabetes if one or both parents had diabetes was 90.3 for men or women with BMI >=40 kg/m2 compared to persons who also had one or both parents with diabetes but had a BMI < 20 kg/m2 (RR = 1). Selected data from these two studies are summarized in Fig. 1 because they demonstrate a remarkable similarity from two diverse populations and also illustrate the potential impact of obesity and weight gain on risk for developing diabetes.



View larger version (18K):
[in this window]
[in a new window]
  		Fig. 1. Relative risk for developing diabetes related to obesity. Values with SEM bars for Pima Indians are from Knowler et al. [10] (open bars) and from female nurses are from Colditz et al. [4] (solid bars).

 
Recently, several persuasive studies [18–20] document that modest changes in lifestyle can protect high-risk individuals from developing diabetes. Other studies strongly indicate that weight loss and increased physical activity slows the development of Type 2 diabetes for high-risk individuals [21–25]. Two recent studies, however, are remarkable for the similarity of their findings. In the Finnish Diabetes Study [19], risk for developing diabetes was reduced by 58% over a six-year period through an intervention fostering weight loss and increased physical activity. The US Diabetes Prevention Program [20] also reported a 58% reduction in risk for diabetes for subjects with the lifestyle intervention compared to the control group. These individuals increased their physical activity by ~50%, lost 6% of their initial body weight and maintained a weight loss of ~3.5% at four years.

One price of intensive glycemic control to achieve normal hemoglobin A1c values is weight gain. While metformin fosters modest weight loss, several classes of oral antidiabetes agents—sulfonylureas, meglitinides, and thiazolidinediones—as well as insulin promote weight gain [15]. In the DCCT, subjects with Type 1 diabetes receiving intensive treatment gained a mean of 4.75 kg [16]. Similarly, in the UKPDS subjects with Type 2 diabetes receiving intensive treatment gained about 5 kg [17]. While these two studies [15,16] reported that intense glycemic control might reduce risk for CHD, the role of glycemic control in risk for CHD is not established [14]. From our previous report [11], we can estimate that a 5 kg weight gain in men would increase CHD risk by almost 30%; the estimated changes in lipids and blood pressure related to a 5 kg weight gain would increase risk by approximately another 20% [11]. For obese diabetic individuals, it is uncertain whether the benefits of glycemic control related to protection from nephropathy and retinopathy are counterbalanced by a potential and substantial increase in risk for CHD.

Obesity or Weight Gain and Risk for CHD
Obesity or weight gain contributes importantly to the risk for diabetes as well as CHD. In 1983, Hubert and colleagues [26] reported that, after adjustment for coexisting risk factors, obesity was an independent risk factor for CHD. Subsequent studies have confirmed and extended these observations. Manson and colleagues [27] reported that even mild overweight significantly increased risk for CHD in middle-aged women. To assess the effect of BMI on risk for CHD, we [11] recently performed a meta-analysis of ten studies. The RR for CHD for women with an initial BMI of 33 kg/m2 was 3.17 (95% Confidence Intervals [CI] of 2.37 to 3.97) compared to women with an entry BMI of 23 kg/m2. For men, the RR for CHD for the higher BMI was 3.19 (95% CI, 2.62 to 3.76) compared to men with the lower BMI at entry. Thus, individuals with a BMI of 33 kg/m2 have a risk for CHD that is ~320% of that for persons with a BMI of 23 kg/m2 [11]. Weight gain after teenage years, independent of initial BMI, is also associated with a substantial risk for CHD. Four studies [11] assessed the risk of weight gain for women after age 18 years old. The variance-adjusted RR was 1.83 (95% CI, -0.14 to 3.80) for women who gained 10–19 kg compared to those with a stable weight [11]. Four studies [11] assessed the risk of weight gain for men after 21 to 25 years of age. The variance-adjusted RR was 1.46 (95% CI, 0.86 to 2.07) for men who gained 10–19 kg compared to those who maintained a stable weight. Data were not available to calculate the CHD risk for obesity at 18 to 25 years of age plus weight gain. Obviously many obese teenagers gain further weight in adult life. Willett et al. [28] estimated this combined risk. Women who have a BMI >=23.3 kg/m2 at age 18 and gain >=20 kg over 14 years of follow-up have a RR of ~6.0 or a risk of 600% compared to women who have a BMI of <23.3 kg/m2 and maintain a stable weight.

Impact of Diet on CHD Risk Factors and Diabetes
Dietary alterations have a major impact on risk factors for CHD. The Adult Treatment Panel III (ATP III) [29] recommends a multifaceted lifestyle approach to reducing risk for CHD including these: obtain 50% to 60% of energy from carbohydrates, emphasizing whole grains, cereals, fruits and vegetables; reduce saturated fat to <7% of energy intake and cholesterol to <200 mg/day; include 20 to 30 grams of fiber daily with 10 to 25 grams of soluble fiber intake; reduce weight; and increase physical activity. The ATP III recognizes overweight and obesity as major, underlying risk factors for CHD and recommends weight reduction and physical activity. This ATP III raised the risk level for persons with diabetes without CHD to a risk level equivalent to presence of CHD. The American Heart Association [30] recommendations for persons with diabetes include these guidelines: reduce energy intake and increase physical activity to achieve and maintain a healthy body weight (defined as a BMI <=25 kg/m2); reduce intake of total dietary fat to <30% of energy; and decrease intake of saturated fat to <7% of energy.

The nutrient composition of the diet has crucial role for achieving and maintaining a desirable body weight (i.e., BMI <=25 kg/m2) and reducing risk for CHD. We recently compared the CHD risk of several popular diets if consumed at a weight-maintaining level for an intermediate-time period compared to consumption of a typical U.S. diet [31]. These calculations suggest that popular low-carbohydrate, high-fat diets would increase serum cholesterol values by almost 30% while a very low-fat, vegetarian diet would decrease serum cholesterol by ~30%. While there are concerns that high-carbohydrate diets may increase fasting serum triglyceride values, in fact, high-carbohydrate, high-fiber diets decrease fasting serum triglycerides values slightly [32,33]. These diets—rich in potassium, magnesium and other minerals—should also decrease blood pressure levels significantly [34]. Thus, high-carbohydrate, high-fiber, low-fat diets rich in vegetables, fruits and whole grains would improve a number of risk factors for CHD [31,34]. These low-fat diets also are effective for long-term maintenance of weight loss [35]. While individuals are receiving intensive counseling by dietitians and active support from primary health care providers, instead of recommending an atherogenic high-fat diet aimed at rapid weight loss it seems prudent to provide instruction in a lifelong, health-promoting diet [34].

Weight loss also significantly decreases risk factors for CHD. Effects of weight loss on several CHD risk factors were recently calculated [11]. A 10 kg reduction in body weight would be expected to produce these changes in risk factors for CHD: fasting serum cholesterol values, -9.9%; LDL-cholesterol, -6.8%; fasting serum triglycerides, -19.3%; HDL-cholesterol, +1.5%; systolic blood pressure, -4.9%; and diastolic blood pressure, -3.8% [11].

Weight loss also dramatically improves glycemic control [36,37] and can produce a remission in diabetes [38,39]. Even before significant weight loss occurs, energy restriction decreases plasma glucose values [36,37] and enhances insulin sensitivity [40]. A decrease in dietary fat intake also enhances insulin sensitivity [41]. In addition to contributing to a desirable weight, dietary components appear to have an important role in retardation of the development of diabetes [19,42,43]. High fat intakes, especially high intakes of saturated fat, seem to increase risk for developing Type 2 diabetes [19,42–44]. Protective dietary practices include generous intakes of these foods: low glycemic index foods [35,42,45], foods rich in cereal fiber and whole grains [42,46] and foods low in saturated fats [22,42]. In general, intake of a "healthy diet" rich in vegetables, fruits and whole grains appears to have significant protective effects [19,42,46]. Dietary practices such as these are likely to slow the evolution of a diabetic diathesis or impaired glucose tolerance into a more florid diabetes state [19].

Cardiovascular Disease and Diabetes
CHD and other atherosclerotic cardiovascular diseases (CVD) are the predominant cause of death for individuals with Type 1 as well as Type 2 diabetes. An estimated 70–80 percent of diabetic individuals die from CVD, indicating that this must be a major target in management of this condition [14,35,47,48]. Diabetes, per se, is a significant risk factor for coronary heart disease, especially in young and middle-aged women. While a number of studies provide RR assessments, the recent report of Gu and colleagues [49] is representative. For US residents, the diabetic man is at threefold greater risk and the diabetic woman is at 4.6-fold greater risk for death from CHD compared to non-diabetic individuals. Consequently, diabetes, per se, appears to be a greater risk factor for CHD than hypercholesterolemia, hypertension, or cigarette smoking [47,48].

Weight Loss Outcomes in Type 2 Diabetes
Because of the challenges in weight management for diabetic individuals, earlier studies over the past 30 years utilized total fasting or very-low-energy diets (VLED) over short periods of time. Greenfield et al. [50] reported that a ten-day total fast with weight loss of 5.1% of initial body weight decreased fasting plasma glucose values of Type 2 diabetic subjects by 64.5% (from 17.2 mmol/L to 6.1 mmol/L). We performed a systematic search of the literature using Medline and the ancestry approach [51] and identified ten studies of obese Type 2 diabetic subjects who were treated for four to six weeks with VLED. These studies provided weight and glucose values at multiple time points with estimates of variance. Statistical analyses were performed with SAS (SAS Online DOC, Version 8, SAS Institute, Cary, NC, 1999). Tests of homogeneity indicated that fixed-effects meta-analyses were associated with significant heterogeneity. Therefore, we performed meta-analyses of all data using random-effects models as previously described [51,52]. In Fig. 2 we summarize the response from nine studies [53–61] using VLEDs with 192 obese subjects with Type 2 diabetes. Over six weeks, subjects lost 9.6% of initial body weight. Fasting plasma glucose values decreased dramatically to ~50% of initial values after two weeks and remained at less than half of the initial values for the six weeks of treatment. Although experimental protocols differed, e.g., oral antidiabetes agents or insulin were usually withdrawn for 3–14 days before initiating diets, there was a remarkable consistency in the response of diabetic individuals to energy restriction. These dramatic responses point clearly to excessive energy intake as a major factor in hyperglycemia of most obese Type 2 diabetic persons [62].



View larger version (19K):
[in this window]
[in a new window]
  		Fig. 2. Effects of weight loss with VLEDs on fasting plasma glucose values for obese persons with type 2 diabetes. Values (with SEM bars) are expressed as percentage of baseline values. Baseline fasting plasma glucose values were 14.0 mmol/L (95% CI, 12.0 to 15.9 mmol/L). Mean values from 10 studies (see text) including 152 subjects.

 
VLEDs have been widely used for diabetes management for ~30 years [63]; Henry and Gumbiner [36] have reviewed their extensive experience. These VLEDs require medical supervision and are intensive and expensive [40]. Consequently, many health professionals now use LEDs providing between 800–1200 kcal/day in their clinical practice. To assess intermediate-term effects of weight loss on glycemic control and CHD risk factors of diabetic individuals, we systematically reviewed the literature over the past 30 years using Medline and the ancestry approach [51]. We analyzed all identified studies using these criteria: obese diabetic subjects with BMI >30 kg/m2 or >120% of ideal body weight (criteria used in some earlier studies); adults >=18 years old; supervised use of energy-restricted diets; achievement of mean weight losses of >=5% of initial body weight at 12 weeks; providing data at >= two time intervals at >=6 weeks of intervention; providing data and variance for body weight and fasting plasma glucose at multiple times; and not using anti-obesity agents. After tabulating data we performed meta-analyses using a random-effects model as previously described [51].

From these studies the association between weight loss and fasting plasma glucose values were examined over a 48-week period (Table 1). Eleven reports provided data from 13 study groups [54,64–73]. These studies provided data for 376 obese diabetic subjects at various time intervals. Subjects lost weight steadily over 16 weeks to a weight that was 14.7% below their initial (baseline) weight. Over the next 32 weeks they regained ~3 kg. Fasting plasma glucose values decreased to 30.5% below initial values at 16 weeks, remained at this level for about eight weeks, and then increased as subjects gained weight. Although study protocols and medication regimens differed across studies, there was a strong association between weight loss and improved glycemia irrespective of the study protocol.


View this table:
[in this window]
[in a new window]
  		Table 1. Effects of Low-Energy and Very-Low Energy Diets on Body Weights and Fasting Plasma Glucose Values for Persons with Type 2 Diabetes

 
To assess the association between weight loss and other cardiovascular risk factors we analyzed all studies providing risk factor data at 12 weeks (Table 2). Fifteen reports provided data for 342 obese diabetic subjects treated in 18 study protocols [54,62,64,65,67,69,70–78]. Weight loss and decrease in fasting plasma glucose values were similar to those noted in Table 1. Weight loss was associated with significant reductions in fasting serum cholesterol, LDL-cholesterol, triglycerides, systolic and diastolic blood pressure. Changes in fasting plasma glucose appear related to baseline values since persons with higher initial values (the nine studies having higher baseline values) have significantly greater reductions (-31.4%; 95% CI, -26.8 to -36.0%) than persons with lower (nine studies with lower baseline values) baseline glucose values (-21.9%; 95% CI, -19.6 to -24.2%). The correlation between baseline glucose and glucose reduction was 0.65 (p < 0.0035). We also compared the association between greater weight loss (the higher nine studies) with lesser weight loss (the lower nine studies). Greater weight loss was associated with significantly (p = 0.012) greater decreases in fasting plasma glucose values than lesser weight loss. The correlation between glucose change and weight loss was 0.56 (p < 0.015). Thus, a 10-kg weight loss over 12 weeks would decrease fasting plasma glucose values by ~25%. Wing and colleagues [37,65] also noted that greater weight loss was associated with greater improvement in glycemia.


View this table:
[in this window]
[in a new window]
  		Table 2. Response of Cardiovascular Risk Factors with Weight Loss for Persons with Type 2 Diabetes

 
Persons with greater weight loss had greater improvements in all their risk factors than persons with lesser weight loss (Table 2). However, the changes in serum cholesterol, LDL-cholesterol, triglycerides and blood pressure did not differ significantly between higher and lower weight losses. Of note, the HDL-cholesterol changes between higher and lower weight losses did differ significantly. Greater weight loss in obese diabetic individuals was associated with a significant increase in HDL-cholesterol values (+3.9, 95% CI, 0.1 to 7.8) while lesser weight loss was associated with a significant decrease in HDL-cholesterol values (-5.9, 95% CI, -9.4 to -2.3). These reductions in risk factors associated with weight loss for diabetic subjects are in the range noted for non-diabetic subjects [11].

Weight Management Considerations
Obesity is difficult to manage in diabetic or non-diabetic individuals. Diabetic individuals may have more difficulty losing weight than non-diabetic individuals because of genetic or metabolic differences, fear of hypoglycemia, antidiabetes medications, other medications, limited physical activity or diet fatigue. Perceived dietary restrictions, such as limitation of carbohydrate intake, may limit therapeutic choices for diabetic individuals. For example, health care professionals may be reluctant to recommend meal replacements, widely used by non-diabetic individuals [79]. Certain centrally acting pharmacologic agents are relatively contraindicated in diabetic individuals because of their cardiovascular effects [80]. Weight loss recommendations for non-diabetic individuals have not been clearly translated into guidelines for diabetic individuals. Expert panels have not reached a consensus about desirable weights for diabetic individuals. Some expert panels recommend that diabetic individuals attain desirable body weights (i.e., non-overweight weights or BMIs of <=25 kg/m2) [81–83] as does the American Heart Association [30]. Other expert panels, including the American Diabetes Association, recommend attaining a reasonable weight (i.e., a weight loss of 5% to 7% of current weight irrespective of initial weight) [84–86]. Finally, there is a therapeutic nihilism among health professionals growing out of frustration with prior failures [5]. All of these factors contribute to lack of strong mandates to aggressively treat obesity in persons with diabetes.

The Evidence Report for Treatment of Obesity in Adults [87] outlines these approaches to treatment of obesity: dietary therapy, physical activity, behavioral therapy, combined therapy (to include the first three modalities), pharmacotherapy and surgery. Most individuals with diabetes receive nutrition counseling from a dietitian or nutrition counselor. Many are instructed in low-energy-diets (LEDs) and encouraged to increase their physical activity. These diets are moderately successful for non-diabetic individuals with weight losses at one year averaging about 7.2% of initial body weight [88]. Less information is available for weights after one year for diabetic individuals. The data that we analyzed (Table 2) suggest that structured interventions with LEDs or VLEDs enable diabetic individuals to maintain weight losses of ~10% of initial body weight at one year. Weight losses in this range offer significant benefits—i.e., reductions in fasting plasma glucose values of ~25% and significant reductions in serum triglycerides—but they often do not lead to "desirable" or non-obese weights. Clearly, optimal cardiovascular-protective effects appear related to achieving non-obese weights.

Our observations suggest that individuals with diabetes should be counseled by their health care providers, especially physicians and dietitians, to achieve non-obese body weights (i.e., BMI <=25 kg/m2) [30,81,82]. This suggestion reflects consideration of achieving desirable glycemic control, serum lipoprotein values and blood pressure as well as reducing risk for CHD. Health professionals should ensure that diabetic individuals understand specific health disadvantages of being obese and that losing weight may be the most important thing they can do to preserve health and longevity. When diabetic individuals appreciate the vital importance of weight loss, they may ask for help in becoming successful in weight management. For persons with BMI values of 25–30 kg/m2, dietetic counseling and a structured LED may be the most cost-effective approach. For persons with BMI values >30 kg/m2, medically supervised LEDs may be the most effective approach [88,89]. Intensive medically supervised LEDs or VLEDs are associated with significantly larger weight losses and about threefold better maintenance of weight loss at five years than less intensive weight loss interventions [88,90]. Higher carbohydrate, higher fiber diets, lower fat diets provide glycemic, lipidemic and weight management advantages for long-term management of obese individuals with Type 2 diabetes [91,92].

Conclusions
Obesity and weight gain are major contributors to development of diabetes and CHD. The risk of diabetes for obese adults can be more than ninetyfold the risk for slender adults. Obese women can have up to a sixfold higher risk for CHD than slender women. Small increases in physical activity and sustained weight losses of 5% of initial body weight can reduce risk for developing diabetes by 58%. Intensive weight loss programs enable obese diabetic individuals to lose 7% to 10% of initial body weights and reduce fasting plasma glucose values by >25% with significant improvements in serum lipoproteins and blood pressure. Optimal diets for improvement of glycemia, lipidemia, and weight and for maintenance of these improvements appear to be higher carbohydrate, higher fiber, lower fat diets. This review leads us to conclude that for many obese diabetic individuals, an emphasis on weight management may be the most important therapeutic task.


   FOOTNOTES
TOP
 FOOTNOTES
ABSTRACT
 INTRODUCTION
 REFERENCES
 
Dr. Anderson discloses the following information: GRANTS/RESEARCH SUPPORT: HCF Nutrition Foundation, Abbott, Andryx, Amylin, Astra-Zenica, Aventis, Bristol-Myers Squibb, Dupont Protein Technologies, GlaxoSmithKline, Health Management Resources, Johnson & Johnson, Merck, Novartis, Novo Nordisk, NutriPharma, Nutricia, Procter & Gamble, Regeneron, Roche, Sanofi, Schering Plough, Slim Fast, Weight Watchers, Wyeth-Ayerst; CONSULTANT: Bristol-Myers Squibb, Dupont Protein Technologies, GlaxoSmithKline, Health Management Resources, Johnson & Johnson, Nutricia, NutriPharma; HONORARIA: Abbott, Bristol-Myers Squibb, Dupont Protein Technologies, GlaxoSmithKline, Merck, Nutricia, NutriPharma, Slim Fast. Dr. Kendall discloses the following information: GRANTS/RESEARCH SUPPORT: Heart and Stroke Foundation of Canada, NSERC Canada, Unilever, Loblaw Brands Ltd., National Starch, Protein Technologies, Almond Board of California, International Nut Council, Quaker, Ceapro, Hain-Celestial Group. Dr. Jenkins discloses the following information: GRANTS/RESEARCH SUPPORT: Heart and Stroke Foundation of Canada, NSERC Canada, Unilever, Loblaw Brands Ltd., National Starch, Protein Technologies, Almond Board of California, International Nut Council, Quaker, Ceapro, Hain-Celestial Group; CONSULTANT: National Starch, NJ; Metcon, Sweden; HONORARIA: Metcon, Unilever, Dupont Protein Technologies, Almond Board of California; SPEAKERS BUREAU: Almond Board of California.

Received July 11, 2002. Accepted March 21, 2003.


   REFERENCES
TOP
 FOOTNOTES
 ABSTRACT
 INTRODUCTION
 REFERENCES
 

  1. Mokdad A, Ford E, Bowman BA, Nelson D, Engelgau MM, Vinicor F, Marks J: The continuing increase of diabetes in the U.S.Diabetes Care24 :412 –412,2001 .[Free Full Text]
  2. Mokdad A, Serdula M, Dietz W, Bowman BA, Marks J, Koplan J: The spread of the obesity epidemic in the United States, 1991–1998.J Am Med Assoc282 :1519 –1522,1999 .[Abstract/Free Full Text]
  3. Pinhas-Hamiel O, Standifer D, Hamiel D, Dolan L, Cohen R, Zeitler P: The type 2 family: a setting for the development and treatment of adolescent type 2 diabetes mellitus.Arch Pediatr Adolesc Med153 :1063 –1067,1999 .[Abstract/Free Full Text]
  4. Colditz GA, Willett W, Rotnitzky A, Manson J: Weight gain as a risk factor for clinical diabetes mellitus in women.Ann Intern Med122 :481 –486,1995 .[Abstract/Free Full Text]
  5. Maggio C and Pi-Sunyer F: The prevention and treatment of obesity. Application to type 2 diabetes.Diabetes Care20 :1744 –1766,1997 .[Medline]
  6. Lean M, Powrie J, Anderson AS, Garthwaite P: Obesity, weight loss and prognosis in type 2 diabetes.Diabet Med7 :228 –233,1990 .[Medline]
  7. Williamson D, Thompson T, Thun M, Flanders D, Pamuk E, Byers T: Intentional weight loss and mortality among overweight individuals with diabetes.Diabetes Care23 :1499 –1504,2000 .[Abstract]
  8. Colditz GA, Willett W, Stampfer M, Manson J, Hennekens C, Arky RA, Speizer F: Weight as a risk factor for clinical diabetes in women.Am J Epidemiol132 :501 –513,1990 .[Abstract/Free Full Text]
  9. Wolf A: Current estimates of the economic cost of obesity in the United States.Obes Res6 :97 –106,1998 .[Medline]
  10. Knowler WC, Pettitt D, Savage PJ, Bennett PH: Diabetes incidence in Pima Indians: contributions of obesity and parental diabetes.Am J Epidemiol113 :144 –156,1981 .[Abstract/Free Full Text]
  11. Anderson JW, Konz EC: Obesity and disease management: Effects of weight loss on co-morbid conditions.Obes Res9 :326S –334S,2001 .[Medline]
  12. Bierman EL: Atherogenesis in diabetes.Arterioscler Thromb Vasc Biol12 :647 –656,1992 .[Free Full Text]
  13. O’Keefe JH, Miles J, Harris W, Moe R, McCallister B: Improving the adverse cardiovascular prognosis in type 2 diabetes.Mayo Clin Proc74 :171 –180,1999 .[Medline]
  14. Duckworth W, McCarren M, Abriara C: Glucose control and cardiovascular complications: the VA diabetes trial.Diabetes Care24 :942 –945,2001 .[Free Full Text]
  15. DeFronzo RA: Pharmacologic therapy for Type 2 diabetes mellitus.Ann Intern Med131 :281 –303,1999 .[Abstract/Free Full Text]
  16. The Diabetes Control and Complications Trial Research Group: Influence of intensive diabetes treatment on body weight and composition of adults with Type 1 diabetes in the Diabetes Control and Complication Trial.Diabetes Care24 :1711 –1721,2001 .[Abstract/Free Full Text]
  17. Turner R, Cull C, Holman R: United Kingdom Prospective Diabetes Study 17: A 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications of non-insulin-dependent diabetes mellitus.Ann Intern Med124 :136 –145,1996 .[Abstract/Free Full Text]
  18. Pan X-R, Li G-W, Hu Y-H, Wang J-X, Yang W-Y, An Z-X, Hu Z-X, Lin J, Xiao J-Z, Cao H-P, Liu P-A, Jiang X-G, Jiang Y-Y, Wang J-P, Zheng H, Zhang H, Bennett PH, Howard BV: Effect of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.Diabetes Care20 :537 –544,1997 .[Abstract]
  19. Tuomilehto J, Lindstrom J, Ericsson J, Valle T, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminnen V, Uusitupa M: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.N Engl J Med344 :1343 –1350,2001 .[Abstract/Free Full Text]
  20. Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.N Engl J Med346 :393 –403,2002 .[Abstract/Free Full Text]
  21. Ericksson K-F, Lingarde F: Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise.Diabetologia34 :891 –898,1991 .[Medline]
  22. Swinburn B, Metcalf P, Ley S: Long-term (5-year) effects of a reduced fat diet intervention in individuals with glucose intolerance.Diabetes Care24 :619 –624,2001 .[Abstract/Free Full Text]
  23. Moore L, Visioni A, Wilson P, Agostino RB, Finkle W, Ellison R: Can sustained weight loss in overweight individuals reduce the risk of diabetes mellitus?Epidemiology11 :269 –273,2000 .[Medline]
  24. Resnick H, Valsania P, Halter J, Lin X: Relation of weight gain and weight loss on subsequent diabetes risk in overweight adults.J Epidemiol Community Health54 :596 –602,2000 .[Abstract/Free Full Text]
  25. Edelstein S, Knowler W, Bain RP, Andres R, Barrett-Conner E, Dowse G, Haffner SM, Pettitt DJ, Sorkin JD, Muller DC, Collins VR, Hamman RF: Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies.Diabetes46 :701 –710,1997 .[Abstract]
  26. Hubert H, Feinleib M, McNamara P, Castelli WC: Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study.Circulation67 :969 –977,1983 .
  27. Manson J, Colditz GA, Stampfer M, Willett W, Rosner B, Monson R, Speizer F, Hennekens C: A prospective study of obesity and risk of coronary heart disease in women.N Engl J Med322 :882 –889,1990 .[Abstract]
  28. Willett W, Manson J, Stampfer M, Colditz GA, Rosner B, Speizer F, Hennekens C: Weight, weight change, and coronary heart disease in women. Risk within the ‘normal’ weight range.J Am Med Assoc273 :461 –465,1995 .[Abstract]
  29. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III).J Am Med Assoc285 :2486 –2497,2001 .[Free Full Text]
  30. Krauss R, Eckel R, Howard B, Appel LJ, Daniels SR, Deckelbaum RJ, Erdman J, Kris-Etherton P, Goldberg I, Kotchen T, Lichtenstein A, Mitch W, Mullis R, Robinson K, Wylie-Rosett J, St. Jeor S, Suttie J, Tribble D, Bazzarre TL: AHA Guidelines Revision 2000: A statement for healthcare professionals from the Nutrition Committee of the American Heart Association.Circulation102 :2296 –2311,2000 .
  31. Anderson JW, Konz EC, Jenkins DJA: Health advantages and disadvantages of weight-reducing diets: a computer analysis and critical review.J Am Coll Nutr19 :578 –590,2000 .[Abstract/Free Full Text]
  32. Anderson JW: Dietary fiber prevents carbohydrate-induced hypertriglyceridemia.Curr Atheroscl Reports2 :536 –541,2000 .
  33. Chandalia M, Garg A, Lutjohann D, von Bergmann K, Grundy S, Brinkley LJ: Beneficial effects of high dietary fiber intake in patients with Type 2 diabetes mellitus.N Engl J Med342 :1392 –1398,2000 .[Abstract/Free Full Text]
  34. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, Bray GA, Vogt TM, Cutler JA, Windhauser MM, Lin PH, Karanja N: A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group.N Engl J Med336 :1117 –1124,1997 .[Abstract/Free Full Text]
  35. Shick S, Wing R, Klem M, McGuire M, Hill J, Seagle H: Persons successful at long-term weight loss and maintenance continue to consume a low-energy, low-fat diet.J Am Diet Assoc98 :408 –413,1998 .[Medline]
  36. Henry R, Gumbiner B: Benefits and limitations of very-low-calorie diet therapy in obese NIDDM.Diabetes Care14 :802 –823,1991 .[Abstract]
  37. Wing R, Marcus M, Blair EH, Watanabe R, Bononi P, Bergman RN: Caloric restriction per se is a significant factor in improvements in glycemic control and insulin sensitivity during weight loss in obese NIDDM patients.Diabetes Care17 :30 –36,1994 .[Abstract]
  38. Pories W, MacDonald Jr K, Morgan E, Sinha M, Dohm G, Swanson C, Barakat HA, Khazanie P, Leggett-Frazier N, Long S, O’Brien K, Caro JF: Surgical treatment of obesity and its effect on diabetes: 10-y follow-up.Am J Clin Nutr55 :582S –585S,1992 .[Abstract/Free Full Text]
  39. Sjostrom CD, Lissner L, Wedel H, Sjostrom L: Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS intervention study.Obes Res7 :477 –484,1999 .[Medline]
  40. Wing R: Use of very-low-calorie diets in the treatment of obese persons with non-insulin-dependent diabetes mellitus.J Am Diet Assoc95 :569 –574,1995 .[Medline]
  41. Bisschop PH, deMetz J, Ackermans MT, Hanno P, Kuipers F, Meijer AJ, Sauerwein HP, Romijn JA: Dietary fat content alters insulin-mediated glucose metabolism in healthy men.Am J Clin Nutr73 :554 –559,2001 .[Abstract/Free Full Text]
  42. Hu F, van Dam R, Liu S: Diet and risk of type II diabetes: the role of types of fat and carbohydrate.Diabetologia44 :805 –817,2001 .[Medline]
  43. Mayer-Davis E: Low-fat diets for diabetes prevention.Diabetes Care24 :613 –614,2001 .[Free Full Text]
  44. Salmeron J, Hu F, Manson J, Stampfer M, Colditz GA, Rimm E, Willett W: Dietary fat intake and risk of type 2 diabetes in women.Am J Clin Nutr73 :1019 –1026,2001 .[Abstract/Free Full Text]
  45. Salmeron J, Ascherio A, Rimm E, Colditz GA, Spiegelman D, Jenkins D, Stampfer M, Wing A, Willett W: Dietary fiber, glycemic load, and risk of NIDDM in men.Diabetes Care20 :545 –550,1997 .[Abstract]
  46. Meyer K, Kushi L, Jacobs D, Slavin J, Sellers T, Folsom A: Carbohydrates, dietary fiber, and incidence of type 2 diabetes in older women.Am J Clin Nutr71 :921 –930,2000 .[Abstract/Free Full Text]
  47. Kannel W: Diabetes and cardiovascular disease.J Am Med Assoc241 :2035 –2038,1979 .[Abstract]
  48. Lotufo P, Gaziano M, Chae CU, Ajani UA, Moreno-John G, Buring JE, Manson J: Diabetes and all-cause and coronary heart disease mortality among US male physicians.Arch Intern Med161 :242 –247,2001 .[Abstract/Free Full Text]
  49. Gu K, Cowie CC, Harris MI: Diabetes and decline in heart disease mortality in US adults.J Am Med Assoc281 :1291 –1297,1999 .[Abstract/Free Full Text]
  50. Greenfield M, Kolterman O, Olefsky J, Reaven G: The effect of ten days of fasting on various aspects of carbohydrate metabolism in obese diabetic subjects with significant fasting hyperglycemia.Metabolism27 :1839 –1852,1978 .[Medline]
  51. Anderson JW, Johnstone BM, Remley DT: Breast-feeding and cognitive function: a meta-analysis.Am J Clin Nutr70 :525 –535,1999 .[Abstract/Free Full Text]
  52. Anderson JW, Johnstone BM, Cook-Newell ME: Meta-analysis of effects of soy protein intake on serum lipids in humans.N Engl J Med333 :276 –282,1995 .[Abstract/Free Full Text]
  53. Nagulesparan M, Savage P, Bennion LJ, Unger R, Bennett PM: Diminished effect of caloric restriction on control of hyperglycemia with increasing known duration of type II diabetes mellitus.J Clin Endocrinol Metab53 :560 –568,1981 .[Abstract]
  54. Hughes T, Gwynne J, Switzer B, Herbst C, White G: Effect of caloric restriction and weight loss on glycemic control, insulin release and resistance, and atherosclerotic risk in obese patients with type II diabetes mellitus.Am J Med77 :7 –17,1984 .[Medline]
  55. Henry R, Schaeffer L, Olefsky J: Glycemic effects of intensive caloric restriction and isocaloric refeeding in noninsulin-dependent diabetes mellitus.J Clin Endocrinol Metab61 :917 –925,1985 .[Abstract]
  56. Amatruda JM, Richeson JF, Welle SL, Brodows RG, Lockwood DH: The safety and efficacy of a controlled low-energy (‘very-low-calorie’) diet in the treatment of non-insulin-dependent diabetes and obesity.J Am Med Assoc148 :873 –877,1988 .
  57. Bauman WA, Schwartz E, Rose HG, Eisenstein HN, Johnson DW: Early and long-term effects of acute caloric deprivation in obese diabetic patients.Am J Med85 :38 –46,1988 .[Medline]
  58. Anderson JW, Brinkman-Kaplan VL, Lee H, Wood CL: Relationship of weight loss to cardiovascular risk factors in morbidly obese individuals.J Am Coll Nutr14 :256 –261,1994 .
  59. Gumbiner B, Wendel J, McDermott M: Effects of diet composition and ketosis on glycemia during very-low-energy-diet therapy in obese patients with non-insulin-dependent diabetes mellitus.Am J Clin Nutr63 :110 –115,1996 .[Abstract/Free Full Text]
  60. Gougeon R, Pencharz P, Sigal R: Effect of glycemic control on the kinetics of whole body protein metabolism in obese subjects with non-insulin dependent diabetes mellitus during iso- and hypoenergetic feeding.Am J Clin Nutr65 :861 –870,1997 .[Abstract/Free Full Text]
  61. Christiansen MP, Linfoot P, Neese R, Hellerstein M: Effect of dietary energy restriction on glucose production and substrate utilization in type 2 diabetes.Diabetes49 :1691 –1699,2000 .[Abstract]
  62. Kelley D, Wing R, Buonocore C, Sturis J, Polonsky K, Fitzsimmons M: Relative effect of calorie restriction and weight loss in noninsulin-dependent diabetes mellitus.J Clin Endocrinol Metab77 :1287 –1293,1993 .[Abstract]
  63. Genuth S: Supplemented fasting in the treatment of obesity and diabetes.Am J Clin Nutr32 :2579 –2586,1979 .[Free Full Text]
  64. Hadden D, Montgomery D, Skelly R, Trimble E, Weaver J, Wilson E, Buchanan KD: Maturity onset diabetes mellitus: response to intense dietary management.Br Med J3 :276 –278,1975 .
  65. Wing R, Marcus M, Salata R, Epstein L, Miaskiewicz S, Blair EH: Effects of a very-low-calorie diet on long-term glycemic control in obese type 2 diabetic subjects.Arch Intern Med151 :1334 –1340,1991 .[Abstract]
  66. Pascale R, Wing R, Blair EH, Harvey J, Guare J: The effect of weight loss on change in waist-to-hip ratio in patients with type II diabetes.Int J Obesity16 :59 –65,1992 .
  67. Anderson JW, Brinkman-Kaplan VL, Hamilton CC, Logan JB, Collins RW: Food-containing hypocaloric diets are as effective as liquid-supplement diets for obese individuals with NIDDM.Diabetes Care17 :602 –604,1994 .[Abstract]
  68. Pascale R, Wing R, Butler BA, Mullen M, Bononi P: Effects of a behavioral weight loss program stressing calorie restriction versus calorie plus fat restriction in obese individuals with NIDDM or a family history of diabetes.Diabetes Care18 :1241 –1248,1995 .[Abstract]
  69. Williams K, Mullen M, Kelley D, Wing R: The effect of short periods of caloric restriction on weight loss and glycemic control in type 2 diabetes.Diabetes Care21 :2 –8,1998 .[Abstract]
  70. Paisey R, Harvey P, Rice S, Belka I, Bower L, Dunn M, Taylor P, Paisey R, Frost J, Ash I: An intensive weight loss programme in established type 2 diabetes and controls: effects on weight and atherosclerosis risk factors at 1 year.Diabet Med15 :73 –79,1998 .[Medline]
  71. Heilbronn L, Noakes M, Clifton PM: Effect of energy restriction, weight loss, and diet composition on plasma lipids and glucose in patients with type 2 diabetes.Diabetes Care22 :889 –895,1999 .[Abstract]
  72. Shige H, Nestel P, Sviridov D, Noakes M, Clifton P: Effect of weight reduction on the distribution of apolipoprotein A-I in high-density lipoprotein subfractions in obese non-insulin-dependent diabetic subjects.Metabolism49 :1453 –1459,2000 .[Medline]
  73. Yip I, Go V, DeShields S, Saltsman P, Bellman M, Thames G, Murray S, Wang H-J, Elashoff R, Heber D: Liquid meal replacements and glycemic control in obese type 2 diabetic patients.Obes Res9 :341S –347S,2001 .[Medline]
  74. Wing R, Epstein L, Paternostro-Bayles M, Kriska A, Nowalk M, Gooding W: Exercise in a behavioural weight control programme for obese patients with type 2 (non-insulin-dependent) diabetes.Diabetologia31 :902 –909,1988 .[Medline]
  75. Uusitupa M, Laakso M, Sarlund H, Mejander H, Takala J, Penttila I: Effects of a very-low-calorie diet on metabolic control and cardiovascular risk factors in the treatment of obese non-insulin-dependent diabetics.Am J Clin Nutr51 :768 –773,1990 .[Abstract/Free Full Text]
  76. Guare J, Wing R, Grant A: Comparison of obese NIDDM and nondiabetic women: short- and long-term weight loss.Obes Res3 :329 –335,1995 .[Medline]
  77. Damsbo P, Hermann L, Vaag A, Hother-Nielsen O, Beck-Nielsen H: Irreversibility of the defect in glycogen synthetase activity in skeletal muscle from obese patients with NIDDM treated with diet and metformin.Diabetes Care21 :1489 –1494,1998 .[Abstract]
  78. Nicholson A, Sklar M, Barnard ND, Gore S, Sullivan R, Browning S: Toward improved management of NIDDM: a randomized, controlled, pilot intervention using a lowfat vegetarian diet.Prev Med29 :87 –91,1999 .[Medline]
  79. Ashley JM, St. Jear ST, Schrage JP, Perumean-Chaney SE, Gilbertson MC, McCall NL, Bovee V: Weight control in the physician’s office.Arch Intern Med161 :1599 –1604,2001 .[Abstract/Free Full Text]
  80. Bray GA, Greenway F: Current and potential drugs for treatment of obesity.Endocr Rev20 :805 –875,1999 .[Abstract/Free Full Text]
  81. Nutrition Committee of the British Diabetic Association’s Professional Advisory Committee: Dietary recommendations for people with diabetes: an update for the 1990s.Diabet Med9 :189 –202,1992 .[Medline]
  82. Diabetes and Nutrition Study Group (DNSG) of the European Association for the Study of Diabetes (EASD) 1: Recommendations for the nutritional management of patients with diabetes mellitus.Diabetes Nutr Metab8 :186 –189,1995 .
  83. Singh R, Rastogi S, Rao P, Das S, Madhu S, Das AK, Sahay B, Fuse S, Beegom R, Sainani G, Shah N: Diet and lifestyle guidelines and desirable levels of risk factors for the prevention of diabetes and its vascular complications in Indians: a scientific statement of the International College of Nutrition.J Cardiovasc Risk4 :201 –208,1997 .[Medline]
  84. Silvis N: Nutrition recommendations for individuals with diabetes mellitus.S Afr Med J81 :162 –166,1991 .
  85. Wolever T, Barbeau MC, Charron S, Harrigan K, Leung S, Madrick B, Taillifer T, Seto C: Guidelines for the nutritional management of diabetes in the new millennium: a position statement by the Canadian Diabetes Association.Can J Diabetes Care23 :56 –69,1999 .
  86. American Diabetes Association: Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications.Diabetes Care25 :202 –212,2002 .[Free Full Text]
  87. Pi-Sunyer FX: Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults.Obes Res6 :51S –209S,1998 .[Medline]
  88. Anderson JW, Konz EC, Frederich RC, Wood CL: Long-term weight-loss maintenance: a meta-analysis of US studies.Am J Clin Nutr74 :579 –584,2001 .[Abstract/Free Full Text]
  89. Anderson JW, Vichitbandra S, Qian W, Krysico RJ: Long-term weight maintenance after an intensive weight-loss program.Am J Coll Nutr18 :620 –627,1999 .
  90. Ayyad C, Andersen T: Long term efficacy of diet treatment of obesity: a systematic review of studies published between 1931 and 1999.Obesity Reviews1 :113 –119,2000 .
  91. Anderson JW: Nutritional management of diabetes mellitus. In Shils M, Olson J, Shike M (eds):"Modern Nutrition in Health and Disease," 9th ed. Philadelphia: Lea & Febiger, pp1365 –1394,1999 .
  92. Anderson JW, Akanji AO, Randles KM: Treatment of diabetes with high fiber diets. In: Spiller GA (ed):"CRC Handbook of Dietary Fiber in Human Nutrition," 3rd ed. Boca Raton, FL: CRC Press, pp373 –400,2001 .



This article has been cited by other articles:


Home page
 Eur J EndocrinolHome page
L. F Van Gaal, S. W Gutkin, and M. A Nauck
Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control?
Eur. J. Endocrinol., June 1, 2008; 158(6): 773 - 784.
[Abstract] [Full Text] [PDF]

Home page
 AMERICAN JOURNAL OF LIFESTYLE MEDICINEHome page
P. M. Janiszewski, T. J. Saunders, and R. Ross
Themed Review: Lifestyle Treatment of the Metabolic Syndrome
American Journal of Lifestyle Medicine, April 1, 2008; 2(2): 99 - 108.
[Abstract] [PDF]

Home page
 J. Nutr.Home page
F. Brighenti
Dietary Fructans and Serum Triacylglycerols: A Meta-Analysis of Randomized Controlled Trials
J. Nutr., November 1, 2007; 137(11): 2552S - 2556S.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes Spectr.Home page
P. Hollander
Anti-Diabetes and Anti-Obesity Medications: Effects on Weight in People With Diabetes
Diabetes Spectr, July 1, 2007; 20(3): 159 - 165.
[Abstract] [Full Text] [PDF]

Home page
 The Diabetes EducatorHome page
C. Carver
Insulin Treatment and the Problem of Weight Gain in Type 2 Diabetes
The Diabetes Educator, November 1, 2006; 32(6): 910 - 917.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
J. W Anderson, S. M Schwartz, J. Hauptman, M. Boldrin, M. Rossi, V. Bansal, and C. A Hale
Low-Dose Orlistat Effects on Body Weight of Mildly to Moderately Overweight Individuals: A 16 Week, Double-Blind, Placebo-Controlled Trial
Ann. Pharmacother., October 1, 2006; 40(10): 1717 - 1723.
[Abstract] [Full Text] [PDF]

Home page
 J. Gerontol. A Biol. Sci. Med. Sci.Home page
M. S. Bonkowski, R. W. Pamenter, J. S. Rocha, M. M. Masternak, J. A. Panici, and A. Bartke
Long-lived growth hormone receptor knockout mice show a delay in age-related changes of body composition and bone characteristics.
J. Gerontol. A Biol. Sci. Med. Sci., June 1, 2006; 61(6): 562 - 567.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Coll. Nutr.Home page
L. A. Bazzano, M. Serdula, and S. Liu
Prevention of Type 2 Diabetes by Diet and Lifestyle Modification
J. Am. Coll. Nutr., October 1, 2005; 24(5): 310 - 319.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
Prevalence of Overweight and Obesity Among Adults With Diagnosed Diabetes--United States, 1988-1994 and 1999-2002
JAMA, February 2, 2005; 293(5): 546 - 547.
[Full Text] [PDF]

Home page
 J. Am. Coll. Nutr.Home page
J. W. Anderson, K. M. Randles, C. W. C. Kendall, and D. J. A. Jenkins
Carbohydrate and Fiber Recommendations for Individuals with Diabetes: A Quantitative Assessment and Meta-Analysis of the Evidence
J. Am. Coll. Nutr., February 1, 2004; 23(1): 5 - 17.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Figures Only
Right arrow Full Text (PDF)
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Anderson, J. W.
Right arrow Articles by Jenkins, D. J.A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Anderson, J. W.
Right arrow Articles by Jenkins, D. J.A.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS